skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Potential treatment options and future research to increase hepatitis C virus treatment response rate

Review

(1663) Views  (726) Full article downloads

Authors: Veronica TenCate, Bruno Sainz Jr, Scott J Cotler, et al

Published Date October 2010 Volume 2010:2 Pages 125 - 145
DOI: http://dx.doi.org/10.2147/HMER.S7193

Veronica TenCate, Bruno Sainz Jr, Scott J Cotler, Susan L Uprichard
Department of Medicine, Section of Hepatology, University of Illinois at Chicago, Chicago, IL, USA

Abstract: Hepatitis C virus (HCV) is a liver-tropic blood-borne pathogen that affects more than 170 million people worldwide. Although acute infections are usually asymptomatic, up to 90% of HCV infections persist with the possibility of long-term consequences such as liver fibrosis, cirrhosis, steatosis, insulin resistance, or hepatocellular carcinoma. As such, HCV-associated liver disease is a major public health concern. Although the currently available standard of care therapy of pegylated interferon α plus ribavirin successfully treats infection in a subset of patients, the development of more effective, less toxic HCV antivirals is a health care imperative. This review not only discusses the limitations of the current HCV standard of care but also evaluates upcoming HCV treatment options and how current research elucidating the viral life cycle is facilitating the development of HCV-specific therapeutics that promise to greatly improve treatment response rates both before and after liver transplantation.

Keywords: interferon, STAT-C, combination therapy, personalized therapy, emerging drug targets, viral life cycle






Readers of this article also read:

Insulin-like growth factor binding protein-3 is required for the regulation of rat oval cell proliferation and differentiation in the 2AAF/PHX model
Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes
Liver stiffness: a novel parameter for the diagnosis of liver disease
Optimal management of hepatorenal syndrome in patients with cirrhosis
Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection
A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
Relationship between serum HBsAg level, HBV DNA level, and peripheral immune cells in patients with chronic hepatitis B virus infection
Pathogenesis and management of alcoholic liver cirrhosis: a review
Boceprevir in the treatment of chronic hepatitis C virus infection
High prevalence of extended-spectrum β-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio